

“5.1. In addition to the amounts paid pursuant to sections 4 and 5, family-type resources shall also be entitled to a daily lump sum of \$1 per user.”

2. Section 18 is amended by replacing “\$300.00” by “\$500”.

3. The following is inserted after section 20:

“20.1. A foster family shall be entitled, as an allowance to cover a child’s personal expenses, to a daily amount of \$3 for each child in foster care.”

4. Section 21 is amended

(1) by replacing “\$48.53” in subparagraph 1 of the first paragraph by “\$77.22”;

(2) by replacing “\$108.35” in subparagraph 2 of the first paragraph by “\$128.44”.

5. Section 26 is amended

(1) by replacing “and 19 to 22” in the first paragraph by “, 19, 20 and 22”;

(2) by inserting the following after the first paragraph:

“The amounts provided for in section 21 shall be, as of 1 January 2004, indexed on the basis of the index referred to in the first paragraph.”

6. These Amendments come into force on the fifteenth day following the date of their publication in the *Gazette officielle du Québec*.

6154

M.O., 2004-002

Order of the Minister of Health and Social Services making the Regulation to amend the Regulation respecting the List of medications covered by the basic prescription drug insurance plan dated 19 January 2004

An Act respecting prescription drug insurance (R.S.Q., c. A-29.01)

THE MINISTER OF HEALTH AND SOCIAL SERVICES,

CONSIDERING section 60 of the Act respecting prescription drug insurance (R.S.Q., c. A-29.01);

CONSIDERING Order 1999-014 dated 15 September 1999 of the Minister of State for Health and Social Services and Minister of Health and Social Services making the Regulation respecting the List of medications covered by the basic prescription drug insurance plan;

CONSIDERING that it is necessary to amend the List of medications attached to that Regulation;

CONSIDERING that the Conseil du médicament has been consulted on the draft regulation;

MAKES the Regulation to amend the Regulation respecting the List of medications covered by the basic prescription drug insurance plan, the text of which is attached hereto.

Québec, 19 January 2004

PHILIPPE COUILLARD,
*Minister of Health
and Social Services*

Regulation to amend the Regulation respecting the List of medications covered by the basic prescription drug insurance plan*

An Act respecting prescription drug insurance (R.S.Q., c. A-29.01, s. 60)

1. The Regulation respecting the List of medications covered by the basic prescription drug insurance plan is amended, in the List of medications attached thereto, in Appendix IV entitled “Exceptional Medications, With Recognized Indications for Payment Purposes”:

(1) by substituting the following for the indications accompanying the medication “FORMOTEROL FUMARATE HYDRATE / BUDESONIDE”:

“FORMOTEROL FUMARATE DIHYDRATE / BUDESONIDE:

◆ for treatment of asthma and other reversible obstructive diseases of the respiratory tract in persons whose control of the disease is insufficient despite the use of an inhaled corticosteroid;

◆ for treatment of persons suffering from moderate or severe chronic obstructive pulmonary disease (COPD) whose COPD is not under control despite the use of an inhaled short-acting β_2 agonist, an inhaled long-acting β_2 agonist and an inhaled anticholinergic agent.

In the case of the medical conditions set out in either of the preceding two paragraphs, persons insured by the Régie de l'assurance maladie du Québec who obtained a reimbursement for an association of formoterol fumarate dihydrate/budesonide or of salmeterol xinafoate/fluticasone propionate within 365 days preceding 1 October 2003 are eligible for a continuation of their treatment;" ;

(2) by substituting the following for the indications accompanying the medication "SALMETEROL XINAFOATE / FLUTICASONE PROPIONATE":

"SALMETEROL XINAFOATE / FLUTICASONE PROPIONATE:

◆ for treatment of asthma and other reversible obstructive diseases of the respiratory tract in persons whose control of the disease is insufficient despite the use of an inhaled corticosteroid ;

◆ for treatment of persons suffering from moderate or severe chronic obstructive pulmonary disease (COPD) whose COPD is not under control despite the use of an inhaled short-acting β_2 agonist, an inhaled long-acting β_2 agonist and an inhaled anticholinergic agent.

LEVETIRACETAM

Tab. + 02247027	Keppra	Lundbeck	120	250 mg 178.80	1.4900
Tab. + 02247028	Keppra	Lundbeck	120	500 mg 218.40	1.8200
Tab. + 02247029	Keppra	Lundbeck	120	750 mg 310.80	2.5900

3. This Regulation comes into force on 28 January 2004.

6159

In the case of the medical conditions set out in either of the preceding two paragraphs, persons insured by the Régie de l'assurance maladie du Québec who obtained a reimbursement for an association of formoterol fumarate dihydrate/budesonide or of salmeterol xinafoate/fluticasone propionate within 365 days preceding 1 October 2003 are eligible for a continuation of their treatment;" ;

(3) by substituting the following for the indications accompanying the medication "TIOTROPIUM BROMIDE MONOHYDRATE":

"TIOTROPIUM BROMIDE MONOHYDRATE:

◆ for treatment of persons suffering from moderate or severe chronic obstructive pulmonary disease (COPD) whose COPD is not under control despite a prior trial with an inhaled short-acting β_2 agonist and inhaled ipratropium ;".

2. The List of medications, attached to the Regulation, is amended by inserting the following in Subdivision 28:12.92, MISCELLANEOUS ANTICONVULSANTS, before the generic name TOPIRAMATE: